[ad_1]
The COVID-19 vaccine is produced by the CNBG Group of China – Photo: GLOBAL TIMES
The Chinese developer of the COVID-19 vaccine has just released this statement to emphasize the safety of both the inactivated vaccine and the recombinant vaccine manufactured by the country.
This move was intended to answer some criticism and doubts. from western countries on the quality of Chinese vaccines and said the country only seeks to “finish first” in the global vaccine race.
China National Biotec Group (CNBG), one of the developers of Chinese vaccines, claims that two of the country’s COVID-19 vaccines have been tested on more than 100,000 people and have had no problems. usually.
There are currently three COVID-19 vaccines licensed for emergency use by Chinese authorities, two of which have been developed by CNBG.
High-risk groups have been vaccinated in China, such as health workers, diplomats or employees in countries severely affected by the epidemic. According to CNBG adviser Zhou Song, these people have been abroad for several months after being vaccinated.
The Chinese newspaper boasted that some of the country’s employees who had been abroad during the outbreak of the outbreak were infected with COVID-19, but there were no cases of those who traveled abroad after being vaccinated. room. This demonstrates the high efficacy of the COVID-19 vaccine developed by China, Zhou said.
The director of CanSino Biologics, another Chinese vaccine developer, also emphasized the safety of its recombinant vaccines, even though the vaccine uses a mechanism similar to that of the vaccine. of the pharmaceutical company AstraZeneca (British-Swedish joint venture) in cooperation with the University of Oxford in England.
Bed sheet Global times He also mentioned the illness of a volunteer that caused AstraZeneca Pharmacy to suspend clinical trials of the late stage vaccine on September 6.
According to AstraZeneca, the suspension of testing activities is to allow independent committees and international regulators to review their safety and effectiveness.
Sinovac Biotech LTD’s COVID-19 vaccine was showcased at the China International Trade and Services Fair (CIFTIS) in Beijing – Photo: AFP
On September 12, the British Medical Administration of Medicine (MHRA) continued to authorize the COVID-19 vaccine produced by AstraZeneca Pharmaceutical Company for clinical testing after being confirmed safe. .
Yang Zhanqiu, deputy director of the department of pathogen biology at Wuhan University, said Global times that the vaccines administered to the Chinese have passed two phases of clinical trials. Consequently, kNone of the vaccinated people had an unusual reaction that demonstrated the safety and efficacy of the Chinese vaccine.
An employee surnamed Wang at the branch of a Chinese state company in Uganda said Global times who had been vaccinated in August and had no unusual symptoms or discomfort.
The employee said he was informed that the Chinese government had arranged flights for the staff to return to Uganda in September and October.
“We will return to Uganda to replace my colleagues there, so that they can reunite with their families. Having vaccines makes my family and I feel more comfortable and safe, and we believe Chinese vaccines,” Wang said.
Tao Lina, a Shanghai-based vaccine expert, said that stopping testing of AstraZeneca’s vaccine does not mean that its vaccines are unsafe, because the mechanism and technique of the COVID-19 vaccine are all the same around the world. and its security level is essentially the same.
Yang said that the likelihood of some unusual reactions, such as fever and edema, is very likely once the vaccine hits the market, as all vaccines will have some side effects. true.
However, so far there is no answer on how long vaccines will protect people. Zhou said lifelong immunity against the virus after receiving a vaccine is minimal, and current experiments show that the vaccine can provide protection for 1-3 years.
